Clinical characteristics and prognostic factors of prolactinomas and growth hormone-secreting adenomas in premenopausal women in China

Xinmei Huang,Yueyue Wu,Jun Liu,Shiqi Li,Li Sheng,Jiong Xu,Tiange Sun,Bingbing Zha,Fang,Wang,Min Yang

2019-01-01

Abstract:Pituitary adenomas, including prolactinomas and growth hormone (GH)-secreting adenomas, are common intracranial tumors in premenopausal women. Few studies have systematically documented the profile of these tumors in premenopausal women in China. Herein, we analyzed the clinical features and prognostic factors of 132 prolactinomas and 39 growth hormone-secreting adenomas treated by transsphenoidal surgery in Chinese premenopausal women. Patients with prolactinomas had smaller tumors (12 mm), higher preoperative prolactin levels (181.9 μg/L), and were younger (28 years) than those with GH-secreting adenomas or with other types of pituitary adenomas. The preoperative level of prolactin positively correlated with tumor size (r = 0.247, P = 0.005) and negatively correlated with age (r = -0.257, P = 0.003) in patients with prolactinomas. The diagnostic cut-off value for the preoperative level of prolactin was 112.2 μg/L with an area under the curve (AUC) of 0.854, a sensitivity of 78%, a specificity of 83%, a positive predictive value (PPV) of 73%, and a negative predictive value (NPV) of 86%. The postoperative remission rate of patients with prolactinomas was 60.7%. Tumor size, preoperative prolactin level, prolactin level on day 1 postsurgery, the postoperative prolactin reduction rate, and the tumor invasiveness were correlated with postoperative remission. However, the predictive factor of positive outcome was only low prolactin level on day 1 postsurgery [odds ratio (OR) = 0.931; 95% confidence interval (CI) = 0.883-0.981] in patients with prolactinomas, with a cut-off value of 20.49 μg/L (AUC: 0.950; sensitivity: 88%; specificity: 95%; PPV: 98%; NPV: 76%) based on logistic regression and receiver-operator characteristic (ROC) analysis. Patients with GH-secreting adenoma had a higher preoperative level of GH (14.3 μg/L), larger tumors (22.5 mm), and were older (41 years) than patients with prolactinoma or with other types of pituitary adenomas. The diagnostic cut-off value for the preoperative level of GH was 2.6 μg/L (AUC: 0.809; sensitivity: 77%; specificity: 83%; PPV: 36%; NPV: 97%), and the postoperative remission rate was 60.7%. Thus, we can conclude that the clinical characteristics and outcomes of prolactinomas and GH-secreting adenomas in premenopausal women were not precisely the same as those in patients with general pituitary adenoma. Prolac tinoma should be suspected in premenopausal women with a prolactin level greater than 112.2 μg/L. A GH level greater than 2.6 μg/L is highly suggestive of GH-secreting adenomas. A prolactin level less than 20.49 μg/L on day 1 postsurgery is a strong independent predictor of remission in Chinese premenopausal women with prolactinoma.